Literature DB >> 20099122

Liposomal adjuvants: preparation and formulation with antigens.

Jean Haensler1.   

Abstract

Many preclinical and clinical results indicate that liposomal systems can serve as effective adjuvants to subunit vaccines by enabling the formulation and delivery of vaccine antigens and immunopotentiators. The adjuvant effect of liposomes usually depends on both the composition of the lipid vesicles and their physical association with the vaccine antigen. This chapter describes methods for the preparation and characterization of sterile small, mostly unilamellar, lipid vesicles and for their association with vaccine antigens. It gives also some recommendations for the optimization of liposomal vaccines in preclinical testing. The most common immunopotentiators used in liposomal adjuvants are also described.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20099122     DOI: 10.1007/978-1-60761-585-9_6

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.

Authors:  Noëlle Mistretta; Bruno Guy; Yves Bérard; François Dalençon; Olivia Fratantonio; Christophe Grégoire; Aurélie Lechevallier; Philippe Lhéritier; Laurent Revet; Monique Moreau; Jean Haensler; Bachra Rokbi
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

2.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

3.  Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.

Authors:  Magdalena K Bielecka; Nathalie Devos; Mélanie Gilbert; Miao-Chiu Hung; Vincent Weynants; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

4.  Potentiating Antigen-Specific Antibody Production with Peptides Obtained from In Silico Screening for High-Affinity against MHC-II.

Authors:  Yoshiro Hanyu; Yuto Komeiji; Mieko Kato
Journal:  Molecules       Date:  2019-08-14       Impact factor: 4.411

5.  Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation.

Authors:  Sumera Y Younis; Christophe Barnier-Quer; Simon Heuking; Vinod Sommandas; Livia Brunner; Nicole Vd Werff; Patrice Dubois; Martin Friede; Clemens Kocken; Nicolas Collin; Ed Remarque
Journal:  BMC Immunol       Date:  2018-01-31       Impact factor: 3.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.